SALT LAKE CITY, Nov. 5, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of
Events in Bali and Rio de Janeiro Bring Together Global Health Leaders to Address Tuberculosis Diagnosis, Treatment and PreventionSALT LAKE CITY, Nov. 5, 2026 /PRNewswire/ -- Co-Diagnostics,
SALT LAKE CITY, Oct. 29, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of
Follow-Up Biopsies Identified High-Grade Lesions or Cervical Cancer in 12 of 20 HPV-Positive Women, Including a Cohort with Predominantly Negative Cytology ResultsCoSara to Exhibit at MICROCON 2026, the Annual Congress
CDSCO Clearance and Commercial Launch in India Anticipated Before Year-End 2026Study Demonstrated 97.3% Sensitivity and 96.0% SpecificityConsistent Performance Across Three Test BatchesIntegrated Mobile and Cloud
Participation in NUWATIN 2026 to Support Advancement of Strategic Manufacturing, Technology Transfer, and Industrial Localization Initiatives Under Saudi Vision 2030Invitation Follows Execution of Manufacturing Facility
Existing Sputum Sample-Preparation Technology Provides Potential Foundation for Plague DiagnosticsDraws on Rapid-Response Experience with COVID-19, Mpox and Ebola Supported by Expanded Manufacturing InfrastructureSALT
Ute Indian Tribe Mosquito Abatement Department to bring PCR-based mosquito surveillance testing in houseSALT LAKE CITY, Oct. 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the
New Executive Order prioritizes improved detection and calls for federal R&D programs for rapid diagnostics for mosquito- and tick-borne diseasesCompany to participate in October 9 Utah Global Health Leadership
Ebola Assay in Development for Decentralized Testing on the Co-Dx PCR PlatformSALT LAKE CITY, Oct. 6, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular
Events Bring Together Global Health Leaders to Examine Tuberculosis and Preparedness for the Next Respiratory PandemicSALT LAKE CITY, Sept. 23, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or
Roundtable discussion, taking place in New York City, will examine the ongoing Ebola outbreak and technologies needed to strengthen future outbreak response.Co-Dx will join officials from the U.S. Department of
SALT LAKE CITY, Sept. 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of
Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and CCo-Diagnostics and ReadyGo target decentralized Ebola detection as the first application of their
Media, analysts and investors are welcome to attend in person or via live webcast, Sept. 16 at 10:30 a.m. ETSALT LAKE CITY, Sept. 15, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the
